SHELTON, CONNECTICUT / ACCESS Newswire / August 18, 2025 / NanoViricides, Inc., a publicly traded company (NYSE American:NNVC ...

Positive Phase 2 results for BX211 demonstrated >40% wound size reduction vs. placebo in diabetic foot osteomyelitis patients ...

Dana-Farber researchers have provided the mechanistic and preclinical evidence needed to support a clinical trial of a new ...

Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the 'Company'), a clinical-stage biopharmaceutical company focused on its Phase ...

SNGX READ THE FULL SNGX RESEARCH REPORT Business Update Dusquetide (SGX945) Granted Orphan Drug Designation for the Treatment ...

Degrees Pharmaceuticals has entered into a clinical study agreement with the Icahn School of Medicine at Mount Sinai in the ...

The platform strategy of using one molecule to target an underlying biological pathway to address many different diseases can ...

Viking Therapeutics, Inc.'s obesity drug VK2735 results reveal no clear edge over leading competitors. Click for why this ...

A research project has reached an important milestone: the first treatment of an animal tumor with radioactive ion beams has ...

Anabelle Terry, a slender, self-possessed 13-year-old, has heard the peanut butter story her entire life. A visit to an ...

The FDA granted breakthrough therapy designation to Ifinatamab deruxtecan for some with extensive-stage small cell lung ...

RedChip Companies, an international investor relations, media, and research firm focused on microcap and small-cap companies, ...